ArticleFrontiers in endocrinology2025
Effectiveness of Xiakucao Oral Liquid combined with methimazole on early thyroid function recovery and treatment compliance in Graves' disease: a real-world retrospective cohort study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To evaluate the effectiveness and treatment compliance of Xiakucao Oral Liquid (XKC) combined with methimazole (MMI) on the early recovery of thyroid function in Graves' disease (GD) patients. Methods: In this retrospective cohort study, GD patients receiving initial treatment at Jieyang People's Hospital from January 2019 to December 2023 were included and divided into XKC+MMI group and MMI group based on the treatment regimen. The association between XKC+MMI and early thyroid function recovery was analyzed using multiple linear regression in the subgroup of patients with post-treatment data available at 3 months. Results: A total of 441 patients were enrolled, among whom 113 (25.6%) patients received XKC+MMI. The proportion of patients receiving XKC+MMI was significantly higher with an initial MMI dose ≥20 mg/day than <20 mg/day (37.1% Conclusions: XKC combination MMI treatment might promote early recovery of thyroid function. However, adherence to and persistence with XKC treatment still need to be improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.